Eiger BioPharmaceuticals Company Description
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development of therapies for hepatitis delta virus (HDV) and other serious diseases.
The company offers Zokinvy for the treatment of Hutchinson-Gilford progeria syndrome and Processing-Deficient Progeroid Laminopathies.
Its product candidates include Lonafarnib, an orally available, farnesylation inhibitor, which has completed Phase 3 clinical trials for HDV infection; Peginterferon Lambda (lambda), which is in clinical development for HDV; lambda, that is in phase II and III investigator studies of mild and moderate COVID-19; and Avexitide, which is in Phase II for the treatment of congenital hyperinsulinism and post-bariatric hypoglycemia.
The company is headquartered in Palo Alto, California. On April 1, 2024, Eiger BioPharmaceuticals, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Northern District of Texas.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 25 |
| CEO | David Apelian |
Contact Details
Address: 2155 Park Boulevard Palo Alto, Delaware Delaware | |
| Phone | 650 272 6138 |
Stock Details
| Ticker Symbol | EIGRQ |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US28249U2042 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. David Apelian M.B.A., M.D., Ph.D. | Chief Executive Officer and Director |
| James Vollins J.D. | General Counsel, Chief Compliance Officer and Corporate Secretary |
| Christopher A. Kurtz | Chief Technical Officer |
| Douglas Staut | Chief Restructuring Officer |